Category: Covid-19

Page 136«..1020..135136137138..150160..»

Brain health in over-50s deteriorated more rapidly during the pandemic – National Institute for Health Research

November 6, 2023

Published: 03 November 2023

Research supported by the NIHRs Biomedical Research Centre in Exeter shows that brain health in people over 50 deteriorated more rapidly during the pandemic. This was true regardless of whether they had COVID-19.

Researchers analysed brain function tests completed by more than 3,000 people based in the UK. Respondents were aged between 50 and 90. The results showed that cognitive decline quickened significantly in the first year of the pandemic. There was a 50% change to the rate of decline across the study group during this time. This figure was higher in those who already had mild cognitive decline before the pandemic.

This trend continued into the second year of the pandemic. This suggests there was an impact beyond the initial 12-month period of lockdowns. The research has been published in The Lancet Healthy Longevity.

The cognitive decline seems to have been exacerbated by a number of factors during the pandemic, including:

Physical activity and treating existing depression can help reduce dementia risk. Getting back into the community and reconnecting with people, can also help maintain brain health.

The 3,000 participants had taken part in the online PROTECT study. It was led by teams at the University of Exeter and the Institute of Psychiatry, Psychology & Neuroscience at Kings College London. The study tested participants short-term memory and ability to complete complex tasks.

The PROTECT study is part of the NIHR Exeter Biomedical Research Centres world-leading Neurodegeneration research theme. The study is a partnership with Kings College London, the NIHR Biomedical Research Centre at South London and Maudsley NHS Foundation Trust, and the NIHR Applied Research Collaboration South West Peninsula. The Exeter BRC has five core research themes aimed at translating scientific discoveries swiftly into benefits to patients.

Anne Corbett, Professor of Dementia Research and PROTECT Study Lead at the University of Exeter, said: "Our findings suggest that lockdowns and other restrictions we experienced during the pandemic have had a real lasting impact on brain health in people aged 50 or over, even after the lockdowns ended. This raises the important question of whether people are at a potentially higher risk of cognitive decline which can lead to dementia. It is now more important than ever to make sure we are supporting people with early cognitive decline, especially because there are things they can do to reduce their risk of dementia later on. So if you are concerned about your memory the best thing to do is to make an appointment with your GP and get an assessment.

Our findings also highlight the need for policy-makers to consider the wider health impacts of restrictions like lockdowns when planning for a future pandemic response."

Professor Dar Aarsland, Professor of Old Age Psychiatry at Kings IoPPN, said: This study adds to the knowledge of the long-standing health-consequences of COVID-19, in particular for vulnerable people such as older people with mild memory problems. We know a great deal of the risks for further decline, and now can add COVID-19 to this list. On the positive note, there is evidence that life-style changes and improved health management can positively influence mental functioning. The current study underlines the importance of careful monitoring of people at risk during major events such as the pandemic.

The PROTECT study is conducted entirely online and is open to new participants aged 40 and over. To find out more, visit the study website.

NIHR has also awarded 1.9 million in funding to develop a new app to monitor brain health in older people. The app is being developed as part of the PROTECT study.

The aim of this study is to help reach people with early cognitive impairment who currently do not get seen by a GP or memory clinic. This is to ensure that those who are in most need are seen as a priority.

See original here:

Brain health in over-50s deteriorated more rapidly during the pandemic - National Institute for Health Research

Brain health in over 50s deteriorated more rapidly during the pandemic, study finds – Science Daily

November 6, 2023

Brain health in over 50s deteriorated more rapidly during the pandemic, even if they didn't have COVID-19, according to major new research linking the pandemic to sustained cognitive decline.

Researchers looked at results from computerised brain function tests from more than 3,000 participants of the online PROTECT study, who were aged between 50 and 90 and based in the UK. The remote study, led by teams at the University of Exeter and the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King's College London, tested participants' short term memory and ability to complete complex tasks.

Through analysing the results from this big dataset, researchers found that cognitive decline quickened significantly in the first year of the pandemic, when they found a 50 per cent change to the rate of decline across the study group. This figure was higher in those who already had mild cognitive decline before the pandemic, according to the research published in The Lancet Healthy Longevity.

This continued into the second year of the pandemic, suggesting an impact beyond the initial 12-month period of lockdowns. The researchers believe this sustained impact to be particularly relevant to ongoing public health and health policy.

The cognitive decline seems to have been exacerbated by a number of factors during the pandemic, including an increase in loneliness and depression, a decrease in exercise and higher alcohol consumption. Previous research has found that physical activity, treating existing depression, getting back into the community and reconnecting with people, are all important ways to reduce dementia risk and maintain brain health.

Anne Corbett, Professor of Dementia Research and PROTECT Study Lead at the University of Exeter, said: "Our findings suggest that lockdowns and other restrictions we experienced during the pandemic have had a real lasting impact on brain health in people aged 50 or over, even after the lockdowns ended. This raises the important question of whether people are at a potentially higher risk of cognitive decline which can lead to dementia. It is now more important than ever to make sure we are supporting people with early cognitive decline, especially because there are things they can do to reduce their risk of dementia later on. So if you are concerned about your memory the best thing to do is to make an appointment with your GP and get an assessment.

"Our findings also highlight the need for policy-makers to consider the wider health impacts of restrictions like lockdowns when planning for a future pandemic response."

Professor Dar Aarsland, Professor of Old Age Psychiatry at King's IoPPN, said "This study adds to the knowledge of the long-standing health-consequences of COVID-19, in particular for vulnerable people such as older people with mild memory problems. We know a great deal of the risks for further decline, and now can add COVID-19 to this list. On the positive note, there is evidence that life-style changes and improved health management can positively influence mental functioning. The current study underlines the importance of careful monitoring of people at risk during major events such as the pandemic."

The PROTECT study, a partnership with King's College, London, is part of the National Institute for Health and Care Research Exeter Biomedical Research Centre's world-leading Neurodegeneration theme research. The Centre, a partnership between The University of Exeter and the Royal Devon University Healthcare NHS Foundation Trust alongside other NHS organisations, has five core research themes aimed at translating scientific discoveries swiftly into benefits to patients.

The paper is entitled 'Cognitive decline in older adults during and after the COVID-19 pandemic: a longitudinal analysis of the PROTECT UK study data' and is published in The Lancet Healthy Longevity.

The PROTECT study is conducted entirely online and is open to new participants aged 40 and over. To find out more, visit: https://www.protectstudy.org.uk

View post:

Brain health in over 50s deteriorated more rapidly during the pandemic, study finds - Science Daily

Covid-19 lockdowns had ‘lasting impact’ on brains of over-50s, study finds – South China Morning Post

November 6, 2023

Covid-19 pandemic lockdowns and other restrictions have had a real, lasting impact on the brain health of people over the age of 50, researchers have suggested.

Researchers from the United Kingdoms University of Exeter and Institute of Psychiatry, Psychology and Neuroscience at Kings College London analysed brain function tests from more than 3,000 people who took part in the so-called Protect Study, launched in 2014 to gain an insight into the brain function of people over 40 over a 25-year period.

The group the researchers assessed, based in the UK, was aged between 50 and 90.

The team compared data from March 2019 and February 2020 to data collected during the pandemics first year (March 2020 to February 2021) and second year (March 2021 to February 2022).

5 nutrients good for brain health that can delay dementia, or prevent it

The pattern continued into the pandemics second year, which researchers said suggests an impact beyond the initial national lockdowns in the UK in 2020 and 2021.

Our findings suggest that lockdowns and other restrictions we experienced during the pandemic have had a real, lasting impact on brain health in people aged 50 or over, even after the lockdowns ended, says Anne Corbett, professor of dementia research and Protect Study lead at the University of Exeter.

She adds that it is now more important than ever to make sure people showing signs of early cognitive decline are supported.

If you are concerned about your memory, the best thing to do is to make an appointment with your [family doctor] and get an assessment, Corbett says.

How 21-day quarantine damages mental health, with long-lasting effects

Our findings also highlight the need for policymakers to consider the wider health impacts of restrictions like lockdowns when planning for a future pandemic response.

We know a great deal of the risks for further decline, and now can add Covid-19 to this list.

The findings have been published in the medical journal The Lancet Healthy Longevity.

See original here:

Covid-19 lockdowns had 'lasting impact' on brains of over-50s, study finds - South China Morning Post

HV.1 and JN.1 Are New COVID-19 Variants Under Scrutiny – Everyday Health

November 6, 2023

With fall well under way and winter soon upon us, public health officials are expecting COVID-19 cases to climb, along with the flu and RSV.

Two COVID-19 variants now being closely monitored are HV.1 and JN.1.

During the week ending October 28, HV.1 rose to become the prevailing strain, accounting for just over one-quarter of all COVID-19 cases, according to the Centers for Disease Control and Prevention (CDC). EG.5, which had been dominant two weeks prior, has fallen to the No. 2 spot, making up about 22 percent of current infections.

As the COVID-19 virus continues to rapidly mutate, the CDC is also keeping close tabs on the emerging JN.1 variant, which was first detected in September 2023 in the United States, and has been spotted in 11 other countries.

Eric Topol, MD, the founder and director of the Scripps Research Translational Institute, has said on X (formerly known as Twitter) that JN.1 is separating from the pack with possible enhanced contagiousness. He wrote in his Substack newsletter Ground Truths, however, that we wont know for a few weeks as to whether JN.1 will be linked with a significant rise in cases or how much immune protection prior infection and vaccination will provide.

What we do know is that both these variants appear to be highly transmissible but not the cause of more severe illness, says William Schaffner, MD, professor of medicine in the division of infectious diseases at Vanderbilt University Medical Center in Nashville, Tennessee.

Dr. Schaffner notes that these variants could be viewed as the grandchildren of the omicron variant, and as such, he expects the latest vaccine formulation to prevent infected people from getting extremely sick and needing to be hospitalized.

As of the end of October, JN.1 has been detected so rarely that it makes up fewer than 0.1 percent of COVID infections in the United States, notes the CDC.

The variant, however, has shown a very fast growth rate in other parts of the world since it was first identified in Luxembourg at the end of August.

Shaun Truelove, PhD, an assistant scientist in the division of global disease epidemiology and control at Johns Hopkins Bloomberg School of Public Health in Baltimore, highlights Iceland as an example. Here JN.1 has quickly spread to make up about 70 percent of COVID-19 infections, according to Dr. Truelove.

He further points out that JN.1 has a distinct mutation that may help it better evade immunity compared with previous strains.

The virus is constantly evolving, constantly trying to escape whatever immunity we have, says Truelove.

As part of a multi-institution team that runs the COVID-19 Scenario Modeling Hub, Truelove expects the United States to see cases continue to rise in the weeks ahead with infections hitting a high in the first month of the new year.

Every single January of this pandemic has been a seasonal peak, he says. Its been extremely consistent. Although recents peaks have been dramatically lower than earlier in the pandemic, the numbers are still much larger than we experience with the flu every year.

With that in mind, health authorities are encouraging the public to get the newest vaccine.

The best thing we have to combat the virus is the vaccine, says Schaffner. Unfortunately, relatively few people have received it so far [7 percent of adults and 2 percent of children, per the CDC]. So Im really worried about what will happen as a consequence of the holidays and all the travel and family gatherings.

He underscores that the vaccine can be especially vital in protecting those most vulnerable, including the elderly and those who are immune-compromised (such as those who are getting chemotherapy for cancer or patients with rheumatic diseases who are taking monoclonal antibodies).

Truelove also encourages people to stay up to date on their COVID-19 vaccines because if you do still get infected, symptoms should be milder and not as long-lasting.

You not only dont want to be that one person who gets hospitalized or dies, you also dont want to be the person whos out of work for a week or out of school, he says.

Go here to read the rest:

HV.1 and JN.1 Are New COVID-19 Variants Under Scrutiny - Everyday Health

Childhood adversity linked to COVID-19 deaths, hospitalizations in … – News-Medical.Net

November 6, 2023

People who endured childhood adversity, like abuse or neglect, were more likely to be hospitalized or die from COVID-19 in adulthood, a new University of Pittsburgh study found. Specifically, higher self-reported childhood adversity was linked to 12-25% higher odds of COVID-19 hospitalization and mortality.

While age, sex, ethnicity, health, and sociodemographic factors have been related to such outcomes throughout the pandemic, this was the first study finding a link between these COVID-19 outcomes and childhood neglect and abuse.

Using the UK Biobank in Great Britain, a team -; lead by Jamie L. Hanson, a researcher in Pitt's Learning Research & Development Center and an assistant professor in psychology in the Kenneth P. Dietrich School of Arts & Sciences -; took a deep dive into information provided by more than 151,200 adults of middle age or older. What the numbers showed was that people who reported "adversity" such as abuse or neglect while children were more likely to die or be hospitalized from COVID-19.

The study was published Nov. 1 in the Journal of Epidemiology and Community Health, the British Medical Association's journal focusing on different social determinants of health.

"These findings highlight how trauma early in life can have long-lasting impacts on health decades later," Hanson said. "We know that COVID-19 is related to excessive hospitalization and death in the UK and in the United States. And there's emerging research finding that facing adversity, abuse or neglect, early in life, could have sizeable effects on physical health.

"But no one had tried to connect these two trends. Knowing a bit more about someone's early development could be important to help reduce disparities in COVID-19."

While Hanson and his co-authors maintain that their work opens the door for more pinpointed and global studies, they believe their findings show there could be a need for policies and interventions to lessen COVID-19 impacts in people who have suffered from such childhood adversity.

We may need targeted interventions for individuals and certain communities affected by childhood adversity to lessen the pandemic's lasting impact. Adversity may lead to risk for negative outcomes and the potential to have long-COVID. We need to complete more work to understand how adversity gets 'under the skin' and increases vulnerability to poor health after COVID-19 infections."

Jamie L. Hanson, researcher in Pitt's Learning Research & Development Center

In other words, as the co-authors wrote, not just COVID-19 but such findings could be used "to limit adversity-related negative outcomes with future pandemics."

Source:

Journal reference:

Hanson, J. L., et al. (2023) Childhood adversity and COVID-19 outcomes in the UK Biobank. Journal of Epidemiology & Community Health. doi.org/10.1136/jech-2023-221147.

Here is the original post:

Childhood adversity linked to COVID-19 deaths, hospitalizations in ... - News-Medical.Net

How the COVID-19 Pandemic Contributed to Diagnostic Bias – Cureus

November 6, 2023

Specialty

Please choose I'm not a medical professional. Allergy and Immunology Anatomy Anesthesiology Cardiac/Thoracic/Vascular Surgery Cardiology Critical Care Dentistry Dermatology Diabetes and Endocrinology Emergency Medicine Epidemiology and Public Health Family Medicine Forensic Medicine Gastroenterology General Practice Genetics Geriatrics Health Policy Hematology HIV/AIDS Hospital-based Medicine I'm not a medical professional. Infectious Disease Integrative/Complementary Medicine Internal Medicine Internal Medicine-Pediatrics Medical Education and Simulation Medical Physics Medical Student Nephrology Neurological Surgery Neurology Nuclear Medicine Nutrition Obstetrics and Gynecology Occupational Health Oncology Ophthalmology Optometry Oral Medicine Orthopaedics Osteopathic Medicine Otolaryngology Pain Management Palliative Care Pathology Pediatrics Pediatric Surgery Physical Medicine and Rehabilitation Plastic Surgery Podiatry Preventive Medicine Psychiatry Psychology Pulmonology Radiation Oncology Radiology Rheumatology Substance Use and Addiction Surgery Therapeutics Trauma Urology Miscellaneous

Read more from the original source:

How the COVID-19 Pandemic Contributed to Diagnostic Bias - Cureus

Examining the Dynamics of COVID-19 Misinformation: Social Media … – Cureus

November 6, 2023

Specialty

Please choose I'm not a medical professional. Allergy and Immunology Anatomy Anesthesiology Cardiac/Thoracic/Vascular Surgery Cardiology Critical Care Dentistry Dermatology Diabetes and Endocrinology Emergency Medicine Epidemiology and Public Health Family Medicine Forensic Medicine Gastroenterology General Practice Genetics Geriatrics Health Policy Hematology HIV/AIDS Hospital-based Medicine I'm not a medical professional. Infectious Disease Integrative/Complementary Medicine Internal Medicine Internal Medicine-Pediatrics Medical Education and Simulation Medical Physics Medical Student Nephrology Neurological Surgery Neurology Nuclear Medicine Nutrition Obstetrics and Gynecology Occupational Health Oncology Ophthalmology Optometry Oral Medicine Orthopaedics Osteopathic Medicine Otolaryngology Pain Management Palliative Care Pathology Pediatrics Pediatric Surgery Physical Medicine and Rehabilitation Plastic Surgery Podiatry Preventive Medicine Psychiatry Psychology Pulmonology Radiation Oncology Radiology Rheumatology Substance Use and Addiction Surgery Therapeutics Trauma Urology Miscellaneous

Read more:

Examining the Dynamics of COVID-19 Misinformation: Social Media ... - Cureus

Impact of COVID-19 on Academic and Psychological Aspects in … – Cureus

November 6, 2023

Specialty

Please choose I'm not a medical professional. Allergy and Immunology Anatomy Anesthesiology Cardiac/Thoracic/Vascular Surgery Cardiology Critical Care Dentistry Dermatology Diabetes and Endocrinology Emergency Medicine Epidemiology and Public Health Family Medicine Forensic Medicine Gastroenterology General Practice Genetics Geriatrics Health Policy Hematology HIV/AIDS Hospital-based Medicine I'm not a medical professional. Infectious Disease Integrative/Complementary Medicine Internal Medicine Internal Medicine-Pediatrics Medical Education and Simulation Medical Physics Medical Student Nephrology Neurological Surgery Neurology Nuclear Medicine Nutrition Obstetrics and Gynecology Occupational Health Oncology Ophthalmology Optometry Oral Medicine Orthopaedics Osteopathic Medicine Otolaryngology Pain Management Palliative Care Pathology Pediatrics Pediatric Surgery Physical Medicine and Rehabilitation Plastic Surgery Podiatry Preventive Medicine Psychiatry Psychology Pulmonology Radiation Oncology Radiology Rheumatology Substance Use and Addiction Surgery Therapeutics Trauma Urology Miscellaneous

See original here:

Impact of COVID-19 on Academic and Psychological Aspects in ... - Cureus

America Is Gambling With Another Low-Vax Winter – The Atlantic

November 3, 2023

Relatively speaking, 2023 has been the least dramatic year of COVID living to date. It kicked off with the mildest pandemic winter on record, followed by more than seven months of quietude. Before hospitalizations started to climb toward their September mini-spike, the country was in the longest period weve had without a peak during the entire pandemic, Shaun Truelove, an infectious-disease modeler at Johns Hopkins University, told me. So maybe its no surprise that, after a year of feeling normalish, most American adults simply arent that worried about getting seriously sick this coming winter.

They also are not particularly eager to get this years COVID shot. According to a recent CDC survey, just 7 percent of adults and 2 percent of kids have received the falls updated shot, as of October 14; at least another 25 percent intends to nab a shot for themselves or their children but havent yet. And even those lackluster stats could be an overestimate, because theyre drawn from the National Immunization Surveys, which is done by phone and so reflects the answers of people willing to take federal surveyors calls. Separate data collected by the CDC, current as of October 24, suggest that only 12 million Americansless than 4 percent of the populationhave gotten the new vaccine, according to Dave Daigle, the associate director for communications at the CDCs Center for Global Health.

CDC Director Mandy Cohen still seems optimistic that the country will come close to the uptake rates of last autumn, when 17 percent of Americans received the updated bivalent vaccine. But for that to happen, Americans would have to maintain or exceed their current immunization clipwhich Gregory Poland, a vaccine expert at Mayo Clinic, told me he isnt betting on. (Already, hes worried about the possible dampening effect of new data suggesting that getting flu and COVID shots simultaneously might slightly elevate the risk of stroke for older people.) As things stand, the United States could be heading into the winter with the fewest people recently vaccinated against COVID-19 since the end of 2020, when most people didnt yet have the option to sign up at all.

This winter is highly unlikely to reprise that first one, when most of the population had no immunity, tests and good antivirals were scarce, and hospitals were overrun. Its more likely to be an encore of this most recent winter, with its relative calm. But thats not necessarily a comfort. If that winter was a kind of uncontrolled experiment in the damage COVID could do when unchecked, this one could codify that experiment into a too-complacent routine that cements our tolerance for sufferingand leaves us vulnerable to more.

To be fair, this years COVID vaccines have much been harder to get. With the end of the public-health emergency, the private sector is handling most distributiona transition thats made for a more uneven, chaotic rollout. In the weeks after the updated shot was cleared for use, many pharmacies were forced to cancel vaccination appointments or turn people away because of inadequate supply. At one point, Jacinda Abdul-Mutakabbir, an infectious-disease pharmacist at UC San Diego, whos been running COVID and flu vaccination in her local community, was emailing her countys office three times a week, trying to get vaccine vials. Even when vaccines have been available, many people have been dismayed to find they need to pay out of pocket for the cost. (Most people, regardless of insurance status, are supposed to be able to receive a free COVID-19 vaccine.)

Read: Falls vaccine routine didnt have to be this hard

The vaccine is now easier to find, in many places; insurance companies, too, seem to be fixing the kinks in compensation. But Abdul-Mutakabbir told me she worries that many of the people who were initially turned away may simply never come back. You lose that window of opportunity, she told me. Even people who havent gotten their autumn shot may be hesitating to try if they expect access to be difficult, as the emergency physician Jeremy Faust points out in his Inside Medicine newsletter.

Plus, because the rollout started later this year than in 2022, many people ended up infected before they could get vaccinated and may now be holding off on the shotor skipping it entirely. And some Americans have simply decided against getting the shot. The CDC reported that 38 percent dont plan to vaccinate themselves or their children; earlier this fall, more than half of respondents in a Kaiser Family Foundation poll said they probably or definitely wouldnt be signing up themselves or their kids. More than 40 percent of those polled by KFF remain doubtful, too, that COVID shots are safedwarfing the numbers of people worried about flu shots, and even about RSV shots, which are newer than their COVID counterparts.

The consequences of low COVID-vaccine uptake are hard to parse. This year, like last year, most Americans have been vaccinated, infected, or both, many of them quite recently. COVIDs average severity has, for many months, been at a relatively consistent low. The last catastrophic SARS-CoV-2 variantone immune-evasive enough to spark a massive wave of sickness, death, and long COVIDarrived two years ago. Barring another feat of viral evolution, perhaps these dynamics have reached something like a stable state, Justin Lessler, an infectious-disease modeler at the University of North Carolina at Chapel Hill, told me. So maybe the most likely scenario is a close repeat of last winter: a rise in hospitalizations and deaths thats ultimately far more muted than any earlier in the outbreak. And the COVID-19 Scenario Modeling Hub, which Lessler co-leads alongside Truelove and a large cohort of other researchers, projects that next year will look a lot like this year, whatever this year ends up looking like, Lessler said.

But predictability is distinct from peace. COVID has still been producing roughly twice the annual mortality that flu does; roughly 17,000 people are being hospitalized for the disease each week. SARS-CoV-2 infections also still carry a risk, far higher than flus, of debilitating some people for years. And I do think were going to experience a winter increase, Truelove told me. Even if this years COVID-vaccine uptake were to climb above 30 percent, models suggest that January hospitalizations could rival numbers from early 2023. Go much lower than that, and several scenarios point to outcomes being worse.

Based on the limited data available, at least one trend is mildly encouraging: Adults 75 and older, the age demographic most vulnerable to COVID and that stands to benefit most from annual shots, also have the highest vaccine uptake so far, at about 20 percent. At the same time, Katelyn Jetelina, the epidemiologist who writes the popular Your Local Epidemiologist newsletter, points out that CDC data suggest that only 8 percent of nursing-home residents are up to date on their COVID shots. That is what keeps me up at night, Jetelina told me. Early National Immunization Surveys data also suggest that uptake is lagging among other groups that might fare less well against COVIDamong them, rural populations, Hispanic people, American Indians and Alaskan Natives, the uninsured, and people living below the poverty line.

Last winter was widely considered to be a bullet dodged, and the reactions to the coming months may be similar: At least its no longer that bad. Since the winter of Omicron, the country has been living with lower vaccine uptake while experiencing lower COVID peaks. But those lower peaks shouldnt undermine the importance of vaccines. Infection-induced immunity, past vaccinations, improvements in treatments, and other factors have combined to make COVID look like a gentler disease. Add more recent vaccination to that mix, and many of those gains would likely be enhanced, keeping immunity levels up without the risks of illness or passing the virus to someone else.

Read: The one thing everyone should know about fall COVID vaccines

As relatively okay as this past year-plus has been, it could have been better. Missed vaccinations still translate into more days spent suffering, more chronic illnesses, more total lives lostan enormous burden to put on an already stressed health-care system, Jetelina told me. For the flu, more Americans act as if they understand this relationship: This year, as of November 1, nearly 25 percent of American adults, and more than 20 percent of American kids, have gotten their fall flu shot. Most of the experts I spoke with would be surprised to see such rates for COVID vaccines even at the end of this rollout.

If last winter was a preview of future COVID winters, our behaviors, too, could predict the patterns well follow going forward. We may not be slammed with the next terrible variant this year, or the next, or the next. When one does arrive, though, as chances are it will, the precedent were setting now may leave us particularly unprepared. At that point, people may be years out from their most recent COVID shot; whole swaths of babies and toddlers may have yet to receive their first dose. Some of us may still have some immunity from recent infections, surebut it wont be the same as dosing up right before respiratory-virus season with protection thats both reliable and safe. Systems once poised to deliver COVID vaccines en masse may struggle to meet demand. Or maybe the public will be slow to react to the new emergency at all. Our choices now will be self-reinforcing, Poland told me. We still wont be doomed to repeat our first full COVID winter. But we may get closer than anyone cares to endure.

The rest is here:

America Is Gambling With Another Low-Vax Winter - The Atlantic

Moderna will break even in 2026: CEO Stphane Bancel – Yahoo Finance

November 3, 2023

Moderna (MRNA) missed Wall Street expectations in the third quarter earnings report released Thursday, as it continues rightsizing the company and putting its COVID-19 vaccine windfall to work. But there's good news ahead: The company expects to finally break even in 2026.

As Moderna moves away from pandemic-level vaccine sales, the company has been busy reducing its manufacturing and infrastructure to match current demand. In addition, it has had to pivot to focus on advancing its pipeline, proving the mRNA platform has potential beyond COVID success.

Moderna now expects its annual sales to be on the lower end of its guidance, at $6 billion, from COVID-19 vaccine sales, which totaled $1.8 billion in the third quarter.

"The volume is not as significant as it once was during the pandemic much of that was to be expected, but it's even probably a little lighter than we thought," said CFO Jamey Mock in an interview with Yahoo Finance Thursday.

The vaccine remains the company's only commercial product to date, as it continues rolling submissions for approval for its RSV vaccine and awaits Phase 3 clinical trial results for its combination COVID and flu vaccine.

In the third quarter, we significantly resized our manufacturing infrastructure to make our COVID-19 franchise profitable for 2024 and beyond. We are preparing to launch multiple products through 2025, including our RSV vaccine. We expect to return to sales growth in 2025 and, through disciplined investment, to break even in 2026," said CEO Stphane Bancel.

For Q3, the company reported a $3.6 billion net loss, including a write-down for unused vaccine doses, and a $9.53 earnings per share loss. Simultaneously, the company reported its market share of COVID doses is 45% year to date in 2023, compared to 36% in 2022.

Mock reiterated Bancel's confidence, telling Yahoo Finance the company can break even by 2026 based on its pipeline and "disciplined investments." That will be largely achieved internally as opposed to looking to fill the pipeline through mergers and acquisitions.

Story continues

"We understand what investors are concerned about" with regard to breaking even and the pipeline, Mock said, adding that he believes the late-stage pipeline has organic growth promise.

The company traded down about 8% Thursday, and the stock is down more than 60% year to date.

Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, care services, digital health, PBMs, and health policy and politics. Follow Anjalee on all social media platforms @AnjKhem.

For the latest earnings reports and analysis, earnings whispers and expectations, and company earnings news, click here

Read the latest financial and business news from Yahoo Finance

Read the original here:

Moderna will break even in 2026: CEO Stphane Bancel - Yahoo Finance

Page 136«..1020..135136137138..150160..»